HealthEquity, Inc. (NASDAQ:HQY – Free Report) – Stock analysts at Zacks Research reduced their Q1 2026 earnings estimates for HealthEquity in a research report issued on Monday, September 30th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.68 for the quarter, down from their previous forecast of $0.69. The consensus estimate for HealthEquity’s current full-year earnings is $2.25 per share.
A number of other research analysts have also recently weighed in on HQY. Wells Fargo & Company lifted their target price on shares of HealthEquity from $107.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, June 20th. JMP Securities reaffirmed a “market outperform” rating and issued a $105.00 price objective on shares of HealthEquity in a research note on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft lifted their target price on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. KeyCorp upped their price target on HealthEquity from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $103.83.
HealthEquity Price Performance
Shares of NASDAQ:HQY opened at $80.27 on Wednesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. The firm has a market cap of $6.98 billion, a price-to-earnings ratio of 87.25, a price-to-earnings-growth ratio of 1.25 and a beta of 0.52. HealthEquity has a fifty-two week low of $61.81 and a fifty-two week high of $88.26. The business has a 50-day simple moving average of $76.42 and a two-hundred day simple moving average of $79.21.
HealthEquity (NASDAQ:HQY – Get Free Report) last released its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The company had revenue of $299.93 million for the quarter, compared to analyst estimates of $284.48 million.
Insider Buying and Selling
In other news, Vice Chairman Stephen Neeleman sold 35,000 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the transaction, the insider now owns 89,769 shares of the company’s stock, valued at $7,168,952.34. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Frank Corvino sold 7,705 shares of HealthEquity stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $81.89, for a total value of $630,962.45. Following the completion of the sale, the director now directly owns 6,070 shares in the company, valued at $497,072.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the completion of the sale, the insider now owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Rise Advisors LLC purchased a new stake in shares of HealthEquity during the first quarter valued at about $28,000. International Assets Investment Management LLC acquired a new stake in HealthEquity in the second quarter worth about $35,000. YHB Investment Advisors Inc. purchased a new position in shares of HealthEquity in the 1st quarter valued at approximately $40,000. Fidelis Capital Partners LLC purchased a new stake in HealthEquity during the 1st quarter worth approximately $42,000. Finally, Parallel Advisors LLC grew its holdings in shares of HealthEquity by 255.5% during the fourth quarter. Parallel Advisors LLC now owns 679 shares of the company’s stock valued at $45,000 after buying an additional 488 shares during the last quarter. 99.55% of the stock is currently owned by hedge funds and other institutional investors.
HealthEquity Company Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Articles
- Five stocks we like better than HealthEquity
- 5 Top Rated Dividend Stocks to Consider
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What Are the U.K. Market Holidays? How to Invest and Trade
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.